The efficacy of anti-PD-1therapy depends on the presentation of neoantigens by major histocompatibility complex (MHC) class I molecules on the surface of cancer cells for surveillance by cytotoxic CD8+ T cells22. This evidence concerns the gene HLA-C and cancer.